Apellis trims staff, shrinks R&D plans to save money in face of looming competition in ophthalmology
Apellis Pharmaceuticals is in cash-saving mode as it looks to ward off a newly-minted competitor in treating a leading cause of blindness.
The drugmaker …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
